Skip to search formSkip to main contentSkip to account menu
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes…
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Breast cancer
View on Elsevier
St. Gallen 2011: Summary of the Consensus Discussion
TLDR
This report summarizes the results of the 2011 international panel voting procedures with regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use.
View on PubMed
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
TLDR
Capecitabine plus trastuzumab appears to be an effective and safe option in a heavily pretreated population of advanced breast cancer patients, and a direct comparison of this regimen with cape citabine monotherapy in this setting is warranted.
View on PubMed
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
TLDR
This brief report by Editors of Breast Care summarizes the results of the 2019 international panel votes with respect to locoregional and systemic treatment as a quick news update for the authors' readers, but it expressly does not intend to replace the official St. Gallen Consensus publication that will follow shortly in Annals of Oncology.
View on PubMed
St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion
TLDR
This report summarizes the results of the 2015 international panel voting procedures with respect to locoregional and endocrine treatment, chemotherapy, targeted therapy, as well as adjuvant bisphosphonate use.
View on PubMed
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
TLDR
Patients with ILC achieved a lower pCR rate and ineligibility for BCS to preoperative chemotherapy, but this did not result in a survival disadvantage, and new strategies to achieve a pCR are warranted.
View on Springer
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
TLDR
Response rate and time to progression are shown to be independent of Her2 status, grading, and progesterone receptor status, which is probably caused by the unique mechanism of action associated with fulvestrant.
View on Publisher
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment
TLDR
This rapid report by the editors-in-chief of Breast Care summarizes the results of the 2017 international panel votings with respect to loco-regional systemic treatment, and does not intend to replace the official St. Gallen Consensus publication.
View on PubMed
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
TLDR
This report summarizes the results of the 2013 international panel voting procedures with regard to loco-regional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License